+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia-Pacific Inhalable Drugs Market 2020-2026

  • ID: 5240884
  • Report
  • February 2020
  • Region: Asia Pacific
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • AstraZeneca Plc
  • Cipla Ltd.
  • GlaxoSmithKline Plc
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
Asia-Pacific Inhalable Drugs Market Size, Share & Trends Analysis Report by Application (Respiratory Diseases and Non-Respiratory Diseases), By Route of Administration (Nasal and Mouth), and Forecast 2020-2026.

The Asia-Pacific inhalable drug market is anticipated to grow at a CAGR of 5.1% during the forecast period (2020-2026). The key factors that drive the growth of the market include the growing geriatric population, rising air pollution, rising awareness about treatment for asthma and COPD along with the significant presence of the market players in the region. In addition, increasing R&D and investments by big pharmaceutical companies in life science research along with innovations are likely to propel the growth of the market in the region. Increased cases of asthma, COPD, diabetes, and other respiratory and non-respiratory diseases especially in China and India are creating demand for proper treatment and hence creating a scope for market growth in the region over the forecast period.

The Asia-Pacific inhalable drug market has been segmented on the basis of the application and route of administration. Based on the application, the market is bifurcated into respiratory disease and non-respiratory diseases. The respiratory disease segment is likely to hold a significant share over the forecast period. Based on the route of administration, the market is segmented into the nasal inhalable drug and mouth inhalable drugs. The mouth segment is likely to contribute a significant share over the forecast period.

Geographically, the Asia-Pacific inhalable drugs market report covers the country-level analysis of China, India, Japan, the Rest of Asia-Pacific. China is estimated to grow significantly during the forecast period. Further, Johnson & Johnson Services Inc., Teva Pharmaceuticals Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Mylan NV, and Cipla Ltd., are some of the prominent players operating in the Asia-Pacific inhalable drugs market.

Research Methodology

The market study of the Asia-Pacific inhalable drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for pharmaceutical companies, drug manufacturers, research institutes, government organizations, regulatory bodies, industry associates & experts, other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. Asia-Pacific Inhalable Drugs Market Research and Analysis by Application
2. Asia-Pacific Inhalable Drugs Market Research and Analysis by Route of Administration

The Report Covers:
  • Comprehensive research methodology of the Asia-Pacific Inhalable Drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Asia-Pacific Inhalable Drugs market.
  • Insights about market determinants which are stimulating the Asia-Pacific Inhalable Drugs market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc
  • Cipla Ltd.
  • GlaxoSmithKline Plc
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Market Determinants
3.1. Motivators
3.2. Restraints
3.3. Opportunities

4. Market Segmentation
4.1. Asia-Pacific Inhalable Drugs Market by Application
4.1.1. Respiratory Diseases
4.1.2. Non- Respiratory Diseases
4.2. Asia-Pacific Inhalable Drugs Market by Route of Administration
4.2.1. Nasal
4.2.2. Mouth

5. Regional Analysis
5.1. China
5.2. India
5.3. Japan
5.4. Rest of Asia-Pacific

6. Competitive Lanscape
6.1. AstraZeneca Plc
6.1.1. Overview
6.1.2. AstraZeneca Plc in Asia-Pacific
6.1.3. AstraZeneca Plc in Inhalable Drugs Landscape
6.1.4. Recent Developments
6.2. Cipla Ltd.
6.3. GlaxoSmithKline Plc
6.4. Johnson & Johnson Services Inc.
6.5. Medisol Lifescience Pvt. Ltd.
6.6. Mylan NV
6.7. Novartis AG
6.8. Pfizer Inc.
6.9. Sanofi SA
6.10. Sumitomo Dainippon Pharma Co. Ltd.
6.11. Teicos Pharma Ltd.
6.12. Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
  • AstraZeneca Plc
  • Cipla Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services Inc.
  • Medisol Lifescience Pvt. Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Teicos Pharma Ltd.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll